Latest Updates...
The NCPE recommends that pembrolizumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*
The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.